THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was ...

Amgen and UCB’s Evenity (romosozumab) has been recommended for use by the NHS in England and Wales by the National Institute for Health and Care Excellence (NICE). The drug can be used to treat ...

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. The FDA announced Tuesday that the drug, called ...

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab) to ...

Amgen recently had two big wins. First, after years of wrangling with the FDA, they finally won approval for their innovative osteoporosis drug, Evenity. Second, Amgen launched Evenity at a price ...

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...

Evenity costs vary based on your insurance coverage and treatment plan. The drug requires a doctor’s visit for injection, and your insurance may bill it through medical coverage rather than ...

Before you begin treatment with Evenity, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. Sharing this information with them may help you prevent ...